Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

被引:28
作者
Leung, L
Srivastava, IK
Kan, E
Legg, H
Sun, Y
Greer, C
Montefiori, DC
Megede, JZ
Barnett, SW
机构
[1] Chiron Corp, Vaccines Res, Emeryville, CA 94608 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
关键词
DNA vaccine; HIV-1; Env; Gag; prime/boost;
D O I
10.1097/00002030-200404300-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To evaluate the immunogenicity of sequence-modified HIV env and gag in baboons using DNA prime and protein boost strategy. Methods: Synthetic sequence-modified HIV gene cassettes were constructed that expressed three different forms of Env proteins, gp140, gp140(mut) and gp140(TM), plus or minus a mutation in the protease-cleavage site. These plasmids were used to immunize baboons (Papio cynocephalus). A group of baboons was also immunized with both env and gag DNA followed by p55Gag virus-like particles (VLP) boost. Results: Modest antibody responses and low or no lymphoproliferative responses were observed following multiple DNA immunizations. In contrast, strong antibodies and substantial antigen-specific lymphoproliferative responses were seen following booster immunizations with oligomeric Env protein (o-gp140(US4)) in MF59. Neutralizing antibody responses were scored against T cell line adapted HIV-1 strains after the protein boosters, but neutralizing responses were low or absent against homologous and heterologous primary isolate strains. In the group receiving both gag and env vaccines, modest antigen-specific antibody and lymphoproliferative responses were scored after the DNA immunizations; these responses were enhanced several-fold upon boosting with the VLP preparations. The addition of Gag antigen did not interfere with Env-specific antibody responses, but there was a negative effect on the levels of Env-specific lymphoproliferation. Conclusions: These results highlight the importance of improving the potency of HIV DANA vaccines by enhanced DNA delivery and prime-boost vaccine technologies to generate more robust immune responses in larger animal models. In addition, care must be taken when immunizations with Env and Gag antigens are performed together. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:991 / 1001
页数:11
相关论文
共 33 条
  • [1] PRIMING OF CD4+ T-CELLS SPECIFIC FOR CONSERVED REGIONS OF HUMAN-IMMUNODEFICIENCY-VIRUS GLYCOPROTEIN GP120 IN HUMANS IMMUNIZED WITH A RECOMBINANT ENVELOPE PROTEIN
    ABRIGNANI, S
    MONTAGNA, D
    JEANNET, M
    WINTSCH, J
    HAIGWOOD, NL
    SHUSTER, JR
    STEIMER, KS
    CRUCHAUD, A
    STAEHELIN, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) : 6136 - 6140
  • [2] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Amara, RR
    Villinger, F
    Altman, JD
    Lydy, SL
    O'Neil, SP
    Staprans, SI
    Montefiori, DC
    Xu, Y
    Herndon, JG
    Wyatt, LS
    Candido, MA
    Kozyr, NL
    Earl, PL
    Smith, JM
    Ma, HL
    Grimm, BD
    Hulsey, ML
    Miller, J
    McClure, HM
    McNicholl, JM
    Moss, B
    Robinson, HL
    [J]. SCIENCE, 2001, 292 (5514) : 69 - 74
  • [3] The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    Barnet, SW
    Lu, S
    Srivastava, I
    Cherpelis, S
    Gettie, A
    Blanchard, J
    Wang, S
    Mboudjeka, I
    Leung, L
    Lian, Y
    Fong, A
    Buckner, C
    Ly, A
    Hilt, S
    Ulmer, J
    Wild, CT
    Mascola, JR
    Stamatatos, L
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (12) : 5526 - 5540
  • [4] BARNETT S, 2003, 13 CENT GARD S RETR, P145
  • [5] Vaccination with HIV 1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
    Barnett, SW
    Rajasekar, S
    Legg, H
    Doe, B
    Fuller, DH
    Haynes, JR
    Walker, CM
    Steimer, KS
    [J]. VACCINE, 1997, 15 (08) : 869 - 873
  • [6] Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys
    Barouch, DH
    Craiu, A
    Santra, S
    Egan, MA
    Schmitz, JE
    Kuroda, MJ
    Fu, TM
    Nam, JH
    Wyatt, LS
    Lifton, MA
    Krivulka, GR
    Nickerson, CE
    Lord, CI
    Moss, B
    Lewis, MG
    Hirsch, VM
    Shiver, JW
    Letvin, NL
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (05) : 2462 - 2467
  • [7] ANTIGENICITY AND IMMUNOGENICITY OF DOMAINS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE POLYPEPTIDE EXPRESSED IN THE YEAST SACCHAROMYCES-CEREVISIAE
    BARR, PJ
    STEIMER, KS
    SABIN, EA
    PARKES, D
    GEORGENASCIMENTO, C
    STEPHANS, JC
    POWERS, MA
    GYENES, A
    VANNEST, GA
    MILLER, ET
    HIGGINS, KW
    LUCIW, PA
    [J]. VACCINE, 1987, 5 (02) : 90 - +
  • [8] The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery
    Briones, M
    Singh, M
    Ugozzoli, M
    Kazzaz, J
    Klakamp, S
    Ott, G
    O'Hagan, D
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (05) : 709 - 712
  • [9] BUDZKO D, 1985, LAB INVEST, V53, P586
  • [10] Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
    Bures, R
    Gaitan, A
    Zhu, TF
    Graziosi, C
    McGrath, KM
    Tartaglia, J
    Caudrelier, P
    EL Habib, R
    Klein, M
    Lazzarin, A
    Stablein, DM
    Deers, M
    Corey, L
    Greenberg, ML
    Schwartz, DH
    Montefiori, DC
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) : 2019 - 2035